Researchprostate cancerpsa testingscreening guidelines
Reduced PSA Screening Raises Stage Four Prostate Cancer
5.0
A study published in Current Oncology found stage 4 prostate cancer cases rose after shifts away from PSA screening between 2010 and 2021. Researchers report a roughly 50% increase in metastatic diagnoses among men aged 50–74 and about 65% in older men, while mortality declines have plateaued. Experts disagree on interpretation, citing PSA inaccuracy, improved imaging, and evolving treatment practices.
Key Points
- 1Report shows metastatic prostate cancer rates rose ~50% (ages 50–74) and ~65% (late 70s) since 2010
- 2Decline in PSA screening aligns with this rise; mortality declines plateaued after prior screening era
- 3Clinicians should reassess screening trade-offs; consider diagnostics, active surveillance, and forthcoming guideline updates
Scoring Rationale
Published peer-reviewed study highlights screening-linked rise in late-stage cases, but medical debate and limited causality reduce impact.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
